Market Overview

US Stock Futures Up Ahead Of Jobless Claims, Factory Orders Data

US Stock Futures Up Ahead Of Jobless Claims, Factory Orders Data

Pre-open movers

US stock futures traded higher in early pre-market trade. Data on weekly jobless claims and nonfarm business productivity for the fourth quarter will be released at 8:30 a.m. ET. Data on factory orders for January will be released at 10:00 a.m. ET. Futures for the Dow Jones Industrial Average surged 24 points to 18,110.00, while the Standard & Poor's 500 index futures rose 2.70 points to 2,099.20. Futures for the Nasdaq 100 index climbed 7.75 points to 4,452.00.

A Peek Into Global Markets

European markets were higher today, with the Spanish Ibex Index rising 0.54%, STOXX Europe 600 Index surging 0.55% and German DAX 30 index gaining 0.75%. French CAC 40 Index climbed 0.83% and London's FTSE 100 Index rose 0.37%.

In Asian markets, Japan's Nikkei Stock Average rose 0.26%, Hong Kong's Hang Seng Index dropped 1.11%, China's Shanghai Composite Index slipped 0.95% and India's BSE Sensex rose 0.23%.

Broker Recommendation
Analysts at B Riley upgraded American Eagle Outfitters, Inc. (NYSE: AEO) from Neutral to Buy and raised the price target from $15.00 to $20.00.

American Eagle's shares climbed 7.69% to close at $15.96 yesterday.

Breaking news

  • Costco Wholesale Corp. (NASDAQ: COST) reported stronger-than-expected earnings for the fiscal second quarter. To read the full news, click here.
  • Mallinckrodt plc (NYSE: MNK) and Ikaria, Inc. a privately-held critical care company, announced today that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will acquire Ikaria, Inc. from a Madison Dearborn-led investor group in a transaction valued at approximately $2.3 billion. To read the full news, click here.
  • Antero Resources Corporation (NYSE: AR) announced today that it has commenced an underwritten public offering of 11,500,000 shares of the Company's common stock. To read the full news, click here.
  • AbbVie (NYSE: ABBV) and Pharmacyclics (NASDAQ: PCYC) today announced a definitive agreement under which AbbVie will acquire Pharmacyclics, and its flagship asset Imbruvica® (ibrutinib), a highly effective treatment for hematologic malignancies. To read the full news, click here.

Related Articles (COST + AEO)

View Comments and Join the Discussion!

Posted-In: B Riley US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets